Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / SNTI - Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting | Benzinga


SNTI - Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting | Benzinga

  • - Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies -

    - Abstracts include new preclinical data demonstrating ongoing progress from collaboration with BlueRock Therapeutics and new technology development to enable Senti's future oncology pipeline products -

    SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held November 1-5, 2023, in San Diego, CA.

    Information about the poster sessions is as follows:

    NOT gate gene circuits expand the range of tumor-associated antigens addressable by CAR-NK and -T cell therapies
    In collaboration with GeneFab LLC
    Abstract number: 257
    Location: Poster Halls A and B1
    Date and time: November 3, 2023, 9:00 am - 7:00 pm PT

    Small-molecule regulated safety switch for improved safety of CAR cell therapies in the brain
    In collaboration with BlueRock Therapeutics and GeneFab LLC
    Abstract number: 24
    Location: Poster Halls A and B1
    Date and time: November 4, 2023, 9:00 am - 8:30 pm PT

    Smart sensor promoters drive state-specific gene circuits to convert immunosuppressive macrophages into an anti-tumor phenotype
    In collaboration with BlueRock Therapeutics and GeneFab LLC
    Abstract number: 430
    Location: Poster Halls A and B1
    Date and time: November 4, 2023, 9:00 am - 8:30 pm PT

    High-throughput discovery of constitutive promoters to drive strong expression of next-generation gene circuits in CAR-NK and -T cells
    Abstract number: 270
    Location: Poster Halls A and B1
    Date and time: November 4, 2023, 9:00 am - 8:30 pm PT

    Following the presentations, copies of the poster presentations will be available on the Scientific Presentations & Publications section of the Senti Bio website.

    About Senti Bio
    Senti Biosciences is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Senti Biosciences Inc.
    Stock Symbol: SNTI
    Market: NASDAQ
    Website: sentibio.com

    Menu

    SNTI SNTI Quote SNTI Short SNTI News SNTI Articles SNTI Message Board
    Get SNTI Alerts

    News, Short Squeeze, Breakout and More Instantly...